Antibodies in Repeated Influenza Vaccination (ARIVA) Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Influenza specific Antibody Responses
Study Overview
Brief Summary
Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maximally diversify the antibody immune response to prevent viral escape. There is, however, growing evidence, that repeated vaccination with very similar viral proteins might limit, instead of broaden, diversification and thereby reduce vaccine efficacy.
The ARIVA Study prospectively studies the immunological impact of repeated influenza vaccination on viral variant recognition and antibody responses in healthy subjects cross-sectionally and over three consecutive vaccination seasons.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •influenza vaccination (QIIV) independent of the study
- •age >18 yo
Exclusion Criteria
- •no vaccination
- •current acute illness
Outcomes
Primary Outcomes
Influenza specific Antibody Responses
Time Frame: Change between baseline and 28 days post-vaccination will be compared
Hemagglutination titers against different H3N2 Influenza strains will be measured and compared between study subjects stratified by number of previous vaccinations
Secondary Outcomes
- Plasmablast generation(Day 7 post-vaccination)
- BCR Repertoire composition(Cross sectional comparison of the BCR repertoire characteristics day 0 and day 28)
Investigators
Christoph Berger
Principal Investigator
University Hospital, Basel, Switzerland